A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Trial Profile

A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Fingolimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFORMS
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 28 Oct 2017 Results of EDSS factor analysis by using data from FREEDOMS, FREEDOMS II and TRANSFORMS studies presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Oct 2017 Results evaluate the proportion of patients with CDI over time while on long-term (up to 8 years) fingolimod treatment in the Phase 3 TRANSFORMS trial and its extensions, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 27 Jun 2017 Results assessing the effect of Fingolimod on Neurofilament Light Chain Blood Levels in patients from two phase III trials (FREEDOMS, TRANSFORMS; n=387) compared with healthy subjects (n=35), presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top